Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

Toon Stegmann, Tobias Kamphuis*, Tjarko Meijerhof, Ellen Goud, Aalzen de Haan, Jan Wilschut

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    44 Citations (Scopus)

    Abstract

    Respiratory syncytial virus (RSV) causes severe respiratory disease in children and the elderly. There is no registered RSV vaccine. Early experimental non-replicating vaccines have been found to exacerbate RSV symptoms upon infection causing enhanced respiratory disease. Here we show that immunization of mice with reconstituted virosomes produced from RSV envelopes and containing the lipopeptide adjuvant (P3CSK4), induces high-titer virus-neutralizing antibodies, and the secretion of IFN-gamma through both MHC-I and MHC-II presentation of antigen, with a balanced Th1/Th2 profile. Immunization with RSV virosomes provides sterilizing immunity to virus challenge in mice and cotton rats, while not producing symptoms of enhanced disease. Therefore, these virosomes represent a promising candidate inactivated RSV vaccine formulation. (C) 2010 Elsevier Ltd. All rights reserved.

    Original languageEnglish
    Pages (from-to)5543-5550
    Number of pages8
    JournalVaccine
    Volume28
    Issue number34
    DOIs
    Publication statusPublished - 2-Aug-2010

    Keywords

    • Respiratory syncytial virus
    • Virosomes
    • Vaccine
    • FORMALIN-INACTIVATED VIRUS
    • COTTON RATS
    • PULMONARY PATHOLOGY
    • F-GLYCOPROTEIN
    • RSV VACCINES
    • DISEASE
    • RECONSTITUTION
    • IMMUNIZATION
    • INFECTION
    • SOLUBILIZATION

    Cite this